QOF

Back to main Menu
Back to Clinical

To be included need to have a code for Proteinuria OR micro-albuminuria

Codes for proteinuria

R110. [D]Proteinuria
R1100 [D]Albuminuria
R110z [D]Proteinuria NOS
C10EK Type 1 diabetes mellitus with persistent proteinuria
C10FL Type 2 diabetes mellitus with persistent proteinuria
K190X Persistent proteinuria, unspecified
Kyu5G [X]Persistent proteinuria, unspecified
K08yA Proteinuric diabetic nephropathy

Codes for microalbuminuria

R1103 [D]Microalbuminuria
C10EL Type 1 diabetes mellitus with persistent microalbuminuria
C10FM Type 2 diabetes mellitus with persistent microalbuminuria

Top

Ace inhibitor contraindications; persistent

14LM. H/O: angiotensin converting enzyme inhibitor allergy
U60C4 [X]Angiotensin-converting-enzyme inhibitors causing adverse effects in therapeutic use
ZV14D [V]Personal history of angiotensin-converting-enzyme inhibitor allergy
TJC77 Adverse reaction to captopril
TJC78 Adverse reaction to enalapril
TJC79 Adverse reaction to ramipril

K0430 Acute renal failure due to ACE inhibitor (v26)

Ace inhibitor contraindications; expiring (12 months)

8I28. Angiotensin converting enzyme inhibitors contraindicated
8I3D. Angiotensin converting enzyme inhibitor declined
8I64. Angiotensin converting enzyme inhibitor not indicated
8I74. Angiotensin converting enzyme inhibitor not tolerated

AII antagonist contraindications: persisting

14LN. H/O: angiotensin II receptor antagonist allergy
U60CB [X]Angiotensin II receptor antagonists causing adverse effects in therapeutic use
ZV14E [V]Personal history of angiotensin II receptor antagonist allergy

AII antagonist contraindications: expiring (12 months)

8I2H. Angiotensin II receptor antagonists contraindicated
8I3P. Angiotensin II receptor antagonist declined
8I6C. Angiotensin II receptor antagonist not indicated
8I75. Angiotensin II receptor antagonist not tolerated
Top

Ace inhibitor prescription codes (prescribed in the last 6 months)

bi...%
bA…%
bk6..%

AII antagonist prescription codes (prescribed in the last 6 months)

bk3.. - bk5z.
bk7.. - bk9z.
bkB..%
bkC..%
bkD..%
bkI..%
bkH..%
bkJ..%
Top

DM 006.1 Rationale

The progression of renal disease in patients with diabetes is slowed by treatment with ACE inhibitors, and trial evidence suggests that these are most effective when given in the maximum dose quoted in the BNF. Although trial evidence is based largely on ACE inhibitors, it is believed that similar benefits occur from treatment with ARBs in patients who are intolerant of ACE inhibitors.

It is recommended that patients with a diagnosis of micro-albuminuria or proteinuria are commenced on an ACE inhibitor or considered for treatment with ARBs.

Further information
SIGN clinical guideline 116 (2010). Management of diabetes.
http://www.sign.ac.uk/guidelines/fulltext/116/index.html

DM 006.2 Reporting and verification

See indicator wording for requirement criteria.

Top

Prepared By Jean Keenan